Galileo Biotech’s Post

🚀 Exciting News in the World of Antibody Drug Conjugates!🔬 🌟 Dive into the latest edition of ADC Digest for this week of May 2024, where groundbreaking advancements are illuminating the field of Antibody Drug 💊 Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer 💊 FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer 💊 GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates Stay tuned for more updates and breakthroughs in the realm of Antibody-Drug Conjugates! #ADC #MedicalInnovations #CancerResearch  #approval #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

Alligator Bioscience AB CMD today at 2pm CET. With upcoming phase 2 data readout on leading product mitazalimab expected in early January 2024 this is an excellent opportunity to learn more. Mitazalimab, that is for Solid metastatic tumors, initially Pancreatic cancer, is an agonistic antibody that targets CD40, a receptor on the dendritic cells of the immune system, which are the cells that detect enemies such as cancer cells. Mitazalimab’s activation of CD40 enables dendritic cells to stimulate the immune response’s weapon Mitazalimab has been shown to induce a potent tumor-targeted immune response and provide long-lasting tumor immunity. In addition, preclinical data have demonstrated how mitazalimab can be used against multiple types of cancer. Turn in here https://lnkd.in/et97wdNT #biotech #cancertreatments #stocks #aktier Søren Bregenholt

NEWS OF THE DAY! Breakthrough: AbbVie's $10 Billion ImmunoGen, Inc. Deal Clinches FDA Approval for Ovarian Cancer Drug!   1. FDA grants full approval for AbbVie's drug Elahere for ovarian cancer treatment 2. Drug approved for folate receptor alpha-positive, platinum-resistant epithelial ovarian cancer patients with up to three prior therapies 3. Elahere developed by ImmunoGen, initially received accelerated approval in November 2022 4. Full approval based on data from Phase 3 study MIRASOL 5. AbbVie acquired ImmunoGen for approximately $10 billion in February =>Please follow Finplate and stay updated with the latest #mergersandacquisitions news. Thanks in advance. To read the news in detail, click below: https://lnkd.in/gRnyjBEd

Join Taiho Oncology on August 1st in recognizing #WorldLungCancerDay.   World Lung Cancer Day is a rallying point to raise awareness of #lungcancer, highlighting key risk factors, as well as screening and treatment options. At Taiho Oncology, we are passionate about advancing patient care and recently joined the lung cancer research community in working to develop potential new lung cancer therapeutic options.   Check out our pipeline to learn more about our lung cancer clinical trials. #TaihoCares

🚨 𝐒𝐦𝐚𝐥𝐥 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐁𝐄𝐀𝐓𝐒 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 𝐢𝐧 𝐥𝐚𝐭𝐞 𝐭𝐫𝐢𝐚𝐥! Summit Therapeutics and Akeso Biopharma have made significant strides in the field of oncology with their bispecific antibody, ivonescimab, in a recent phase 3 trial conducted in China. 👉 The trial, named HARMONi-2, demonstrated ivonescimab's superiority over Keytruda (a PD-1 inhibitor) in treating non-small cell lung cancer (NSCLC), particularly in patients with PD-L1-expressing tumors. Ivonescimab showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Keytruda monotherapy. The positive results have sparked optimism among analysts and industry experts, with some calling the trial win a milestone achievement. However, the partners still face challenges in gaining approval outside of China, particularly in the U.S. Read more below 👇 #biotech #oncology #biopharma #bispecifics

A short and sweet article about the combination of ADCs with immune modulators!

Divarasib: Great Timing for Positive Data Makes This KRAS Inhibitor a Big Deal | https://lnkd.in/gmvSbK-t Genentech's divarasib (GDC-6036) is a covalent inhibitor of KRASG12C in Ph. III in patients with non-small cell lung cancer (NSCLC) (NCT03178552), making it the third most advanced KRASG12C inhibitor after the accelerated approvals of Amgen’s sotorasib and Mirati’s adagrasib. Surprisingly strong efficacy recently observed with the molecule positions it well at a pivotal moment following a regulatory setback with sotorasib and Bristol Myers Squibb’s timely $5B+ acquisition of adagrasib and Mirati Therapeutics This case study discusses why divarasib is a big deal and scientific highlights including a long human half-life and a remarkable kiloscale atropisomer-selective synthesis of the molecule. Full article: https://lnkd.in/gmvSbK-t

RLY-2608: An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models | https://lnkd.in/gxRdfabf RLY-2608 is an oral, mutant-selective PI3Kα allosteric inhibitor discovered by Relay Therapeutics that targets a cryptic pocket near the ATP-binding site. Given the challenges and toxicities associated with WT PI3Kα inhibition like hyperglycemia and rash, there's a growing need for next-generation mutant-selective PI3Kα allosteric inhibitors. Currently undergoing Ph. I clinical trials, RLY-2608 holds promise as a single agent and in combination with fulvestrant for HR+/HER2- breast cancer treatment. Explore the notable discovery strategy, mutant selectivity profile and novel mechanism of selectivity, how it compares to other molecules, preclinical activity, recent clinical developments, and more in this review article. Full Article: https://lnkd.in/gxRdfabf

[Clinical Trials] ImmunityBio, Inc.'s phase 2/3 trial of Anktiva assesses CR incidence and survival in bladder cancer https://lnkd.in/gSfDi5uP Johnson & Johnson's phase 3 trial of nipocalimab reaches primary endpoints in gMG and SjD studies https://lnkd.in/gmtEQksG Vertex Pharmaceuticals' phase 3 trials of Vanza Triple meets primary endpoint matches TRIKAFTA in cystic fibrosis lung function improvement https://lnkd.in/geZbXqfV Sangamo Therapeutics, Inc. Therapeutics' phase 1/2 trial of ST-920 exhibits sustained α-Gal A activity in Fabry disease https://lnkd.in/gtAjZjEZ GSK's phase 3 trial of Blenrep in multiple myeloma indicates extended progression-free survival over daratumumab combination https://lnkd.in/gbgkYXGn [Deals] Novartis Signs Agreement to Acquire MorphoSys for EUR 2.7 Billion Securing Ownership of phase 3 BET Protein Inhibitor Pelabresib and Tulmimetostat https://lnkd.in/gPYc2DE8

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, according to data released ahead of ASCO, but four participants in the trial died. Patient deaths are not unheard of in early-stage testing. But these cases could give pause to other drug developers, as Johnson & Johnson is one of the first to report clinical data on a next-generation isotope that is theorized to be safer. It may also hamper how much Johnson & Johnson can increase the dose of JNJ-6420 in order to boost the response rate. What do you think about the radiopharmaceutical data? #radiopharmaceuticals #ASCO #ASCO2024 #pharma #cancer #oncology #drugdevelopment #clinicaltrials #radiation